Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.735,35
0,38%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR) Notizie

UTHR

United Therapeutics (UTHR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:UTHR
DataOraFonteTitoloSimboloCompagnia
31/05/202413:00Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:UTHRUnited Therapeutics Corporation
30/05/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
14/05/202422:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
01/05/202412:30Business WireUnited Therapeutics Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
26/04/202420:02Business WireCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202415:00Business WireUnited Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202413:00Business WireUnited Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024NASDAQ:UTHRUnited Therapeutics Corporation
16/04/202413:00Business WireUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
26/03/202412:00Business WireUnited Therapeutics Announces the First Comprehensive Review Publication on XenotransplantationNASDAQ:UTHRUnited Therapeutics Corporation
25/03/202412:00Business WireUnited Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase ProgramNASDAQ:UTHRUnited Therapeutics Corporation
05/03/202412:00Business WireUnited Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:UTHRUnited Therapeutics Corporation
27/02/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:UTHRUnited Therapeutics Corporation
27/02/202412:00Business WireUnited Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
21/02/202412:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:UTHRUnited Therapeutics Corporation
21/02/202412:00Business WireUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
21/02/202411:55Business WireUnited Therapeutics Commences Litigation to Ensure Fairness in the Drug Review ProcessNASDAQ:UTHRUnited Therapeutics Corporation
14/02/202422:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:UTHRUnited Therapeutics Corporation
14/02/202412:00Business WireUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024NASDAQ:UTHRUnited Therapeutics Corporation
29/12/202312:00Business WireUnited Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
22/12/202315:51Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:UTHRUnited Therapeutics Corporation
14/12/202320:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
13/12/202316:03Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:UTHRUnited Therapeutics Corporation
13/12/202315:15Business WireUnited Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and MergerNASDAQ:UTHRUnited Therapeutics Corporation
12/12/202312:00Business WireUnited Therapeutics and Miromatrix Medical Announce Successful Tender OfferNASDAQ:UTHRUnited Therapeutics Corporation
07/12/202312:00Business WireUnited Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024NASDAQ:UTHRUnited Therapeutics Corporation
13/11/202312:06Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:UTHRUnited Therapeutics Corporation
01/11/202321:50Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:UTHRUnited Therapeutics Corporation
01/11/202311:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:UTHRUnited Therapeutics Corporation
01/11/202311:00Business WireUnited Therapeutics Corporation Reports Third Quarter 2023 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
31/10/202311:05Business WireUnited Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary FibrosisNASDAQ:UTHRUnited Therapeutics Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:UTHR

La tua Cronologia

NASDAQ
FUYQHX
Ubs Yield at a Reasonabl...
COIN
BTRRRUSD
BTRIPS
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network